Dr Steven O'Day, speaking at the 2010 ASCO conference: A Phase III trial featured in an ASCO plenary session finds that patients with advanced, previously treated melanoma who received the monoclonal antibody ipilimumab lived 34 percent longer than those who received the immune-stimulating gp100 peptide vaccine. The clinical trial is the first randomised study to find an improvement in survival for advanced melanoma, which has few treatment options.